Peninsula Land to Outperform – ENAM

ENAM Securities Research is recommending Peninsula Land as an outperformer with a price target of Rs 719.

Peninsula has applied for necessary approvals to change the land usage for its Dawn Mills property, in Lower Parel, from commercial to an IT Park, thereby doubling the FSI and saleable area to ~1.2mn sq. ft., resulting in a significant upside in our valuations. The selling prices at Sewri currently range between ~Rs 13,000 psf to 14,000 psf (Ashok Gardens project) and at Kurla, between ~Rs 13,500 psf to 14,500 psf (Peninsula Technopark project). The company expects to receive Rs 25-27bn in revenues over the next 3 years from Dawn Mills Project.

ENAM believes that the company is a high quality real estate player in Mumbai with a strong focus on the commercial segment. At CMP of Rs 450, the stock trades at a significant discount of ~29% to NAV of Rs 637.

ENAM’s base Case Target for the Stock is Rs 719 and the bear case target is Rs 550 based on Sum of Parts Evaluation.

KLG Syetel Bags Order from Rajasthan Govt

KLG Systel has been awarded orders worth over Rs 67 crore from Governments of Rajasthan and Haryana. The projects covered in this order include that of revenue management for power utilities and boosting the power infrastructure in the states of Haryana and Rajasthan. The company shall, in the course of these project deployments, use its innovative SG61 technology to reconcile and manage the power distribution in utilities. The company has extensive experience and expertise in the Utilities business and will use state of art project management tools for timely execution of these projects. These projects are expected to be completed by March 2008.

The company is an IBM premiere ISV in India and is also now certified by IBM for SOA. SOA enables organization to build a scalable architecture capable of talking to legacy systems. The company has been recently announced as an independent software vendor by SAP and KLG’ S Vidushi has obtained net weaver certification from SAP. The company was also very recently awarded a SAP-IS utilities order from Jamshedpur utilities.

Abbott India to Buy Back Shares

Abbott India announced that a meeting of the board of directors of the company will be held on 5 September 2007, to consider a proposal for buyback of a portion of fully paid equity shares of the company. The buyback price to be determined by the board will not exceed Rs 650 per equity share, it said.

Net profit of Abbott India rose 34.66% to Rs 18.30 crore on 18.80% rise in sales to Rs 154.04 crore in Q2 May 2007 over Q2 May 2006.

Infotech Enterprises Alliance With Boeing

Infotech Enterprises has announced that Infotech Enterprises America, (Infotech), a global geospatial and engineering consulting and professional services firm has formed a strategic alliance partnership with Continental DataGraphics (CDG), a subsidiary of the boeing company.

The alliance with Infotech will also enable CDG to be more responsive to growing demands from its customers to develop and deliver new solution offerings in an accelerated timeframe. CDG is proactively developing new strategic partnerships with companies such as Infotech to further globalize its business and to actively seek out opportunities for growth in a broader marketplace.

CDG specializes in the creation, production, and distribution of complex engineering publications. Its comprehensive services include technical authoring and illustration services, digital imaging, and hosted portal services supporting multiple market segments in the United States and Europe, including aviation, aerospace and defense, manufacturing, energy and government. CDG has developed complex technical and engineering publications for Boeing aircraft and other heavy equipment manufacturers for many decades.

Buy ABB + Nicholas Piramal India – Citigroup

Citigroup Research which had a BUY recommendation on ABB has revised its target price upwards to Rs 1,266. Current market Price is Post Stock Split from Face Value Rs 10 to Rs 2.

Citi expects earnings CAGR of 49% (from 42% earlier) over CY06-09E with RoEs at the ~37% level, driven by sales CAGR of 42%. Target price is based on a P/E of 30x FY09E at a ~30% premium to BHEL given: 1] EPS CAGR of 49%; 2] RoEs of ~37%; 3] Access to parent technology; and 4] ABB India’s importance in the ABB Group.

ABB China grew sales at a CAGR of 33% over a 7-year period between CY98 to CY05. ABB India may find it possible to repeat this feat in India given India is the fastest growing T&D market in the world, a fact corroborated by both ABB an Areva. India is not only a promising domestic market, where ABB is well-positioned as a market leader in power and automation technologies but also a global sourcing hub; global R&D centre; and regional excellence centre.

Citi has also recommended a BUY on Nicholas Piramal India as the stock will unlock the value from proposed demerger of R&D unit – NCE Research. NPIL’s focus on NCE R&D has been rising and it is working on 13 NCEs (3 in the clinic). R&D/sales was up from 1.2% in FY03 to 5.2% in FY07 (66% CAGR) and is set to rise to 5.7% in FY08E.

First-cut calculations indicate that a demerger would raise FY09E and FY10E EPS 12-16% and 11-15% respectively. Besides, the street has treated NPIL’s NCE R&D as a cost, thereby reducing the company’s overall valuation. On demerger, if the NewCo is listed, expect the Street to assign some value to this as well, thus unlocking value for shareholders. Citi sets a target price of Rs 345 on Nicholas Piramal India.

In a separate Research report, Sharekhan securities has set a Target price of Rs 326 on Nicholas Piramal India Ltd.

Elder Pharma Acquires Biomeda in Bulgaria

Elder Pharmaceuticals has reportedly acquired 51% stake in Biomeda Group in Bulgaria for euro 5 million (around Rs 28 crore) in an all-cash deal. Biomeda Group is a leading pharma group in Bulgaria with a turnover of about 10-12 million euros. With the acquisition, Elder will see the launch of many more products in Europe. Biomeda is Elder’s second acquisition in less than 45 days.

On 26 July 2007 it had acquired a 20% stake in UK’s NeutraHealth Plc for 5.63 million pounds sterling (Rs 47crore). Neutra Health has three subsidiaries selling neutraceutical products such as vitamins, health supplements and over-the-counter medicine. Neutra Health has a turnover of 23 million sterling pounds and a market capitalisation of close to 16.8 million sterling pounds.

Elder’s net profit rose 15% to Rs 15.08 crore in Q1 June 2007 over Q1 June 2006. Sales moved up 15.6% to Rs 120.69 crore.

1 88 89 90 91 92 173